Taysha Gene Therapies, Inc.
TSHAUnited States
25 filed reports · 322 financial concepts · 1 earnings calls · 0 media appearances
Filed reports
25 reports · Sep 2020 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 18 | 2,305 | Sep 2020 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 6 | 1,788 | Dec 2020 to Dec 2025 |
| Annual · 10-K/ASEC EDGAR | 1 | 1 | Dec 2022 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 11, 2026 | 297 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 6, 2026 | 184 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 19, 2026 | 537 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 4, 2025 | 201 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 12, 2025 | 136 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 15, 2025 | 136 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 26, 2025 | 345 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 13, 2024 | 134 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 12, 2024 | 132 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 14, 2024 | 133 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Mar 19, 2024 | 312 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 14, 2023 | 141 | Open |
Financial data
322 concepts · 4,094 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial322 concepts · 4,094 facts · Dec 2018 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations35 · Sep 2019 to Jun 2026
- Stockholders equity (US GAAP)35 · Sep 2019 to Jun 2026
- Accrued expenses and other liabilities32 · Mar 2020 to Jun 2026
- Accrued professional fees current32 · Dec 2019 to Jun 2026
- Accrued research and development32 · Dec 2019 to Jun 2026
- Additional paid in capital32 · Dec 2019 to Jun 2026
- Assets32 · Dec 2019 to Jun 2026
- Assets current32 · Dec 2019 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect32 · Mar 2020 to Jun 2026
- Common stock par or stated value per share32 · Dec 2019 to Jun 2026
- Common stock shares authorized32 · Dec 2019 to Jun 2026
- Common stock shares issued32 · Dec 2019 to Jun 2026
- Common stock shares outstanding32 · Dec 2019 to Jun 2026
- Depreciation32 · Mar 2020 to Jun 2026
- General and administrative expense (US GAAP)32 · Mar 2020 to Jun 2026
- Increase decrease in accounts payable32 · Mar 2020 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets32 · Mar 2020 to Jun 2026
- Liabilities32 · Dec 2019 to Jun 2026
- Liabilities and stockholders equity32 · Dec 2019 to Jun 2026
- Liabilities current32 · Dec 2019 to Jun 2026
- Net cash provided by used in investing activities32 · Mar 2020 to Jun 2026
- Net cash provided by used in operating activities32 · Mar 2020 to Jun 2026
- Net income loss32 · Mar 2020 to Jun 2026
- Net income loss available to common stockholders basic32 · Mar 2020 to Jun 2026
Segments
Figures broken down by business line, region, product or another axis the company reports on.
No segment breakdowns.
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
1 calls · Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 11, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.